We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





CerTest Biotec and BD Secure CE Mark for Combination COVID-19, Influenza, RSV Test on BD MAX System

By LabMedica International staff writers
Posted on 22 Oct 2020
CerTest Biotec (Zaragoza, Spain), along with Becton, Dickinson and Company (BD Franklin Lakes, NJ, USA), have announced that the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit adapted for the BD MAX System has been CE marked.

The kit allows BD MAX System users to run a single module that tests concurrently for COVID-19 and Influenza (Flu) and Respiratory Syncytial Virus (RSV). More...
The BD MAX System, a molecular diagnostic platform, is widely used in hundreds of laboratories across Europe. Each unit can return results in two to three hours and is capable of analyzing hundreds of samples over a 24-hour period. The CerTest tests snaps into the test-specific position on the BD MAX ExK TNA extraction strip, supplied by BD. VIASURE SARS-CoV-2 (N1+N2) Real Time PCR Detection Kit for the BD MAX System and the VIASURE Flu A, Flu B & RSV Real Time PCR Detection Kit for the BD MAX System are sold through BD's network and are not available for sale in the US.

"The new CerTest kit will provide rapid COVID-19 diagnostic capabilities that can be run individually or combined with detection of Flu A, Flu B and RSV A and B," said Nelson Fernandes, managing director of CerTest Biotec. "As we enter flu season, the ability to test for both COVID-19 and Flu at the same time will speed diagnosis and, ultimately, treatment."

"Together with CerTest, we can offer our customers in Europe a complete solution for COVID-19 diagnostics during the winter season," said Nikos Pavlidis, vice president of Molecular Diagnostics and Women's Health for BD. "By leveraging our significant installed base and the versatility of the BD MAX System, this test will greatly enhance capacity for SARS-CoV-2 and Influenza testing, enabling clinicians to rapidly diagnose patients and help reduce the spread of COVID-19."

Related Links:
Becton, Dickinson and Company
CerTest Biotec

Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Portable Electronic Pipette
Mini 96
New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.